Augustine Therapeutics has received €1.2 million (about $1.4 million) in funding for a research project that will seek to…
Marisa Wexler, MS
Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Marisa Wexler, MS
More research is needed into whether different types of exercise can provide benefits to people with Charcot-Marie-Tooth disease (CMT),…
A never-before-reported mutation in the gene MFN2 was found to cause a severe form of Charcot-Marie-Tooth disease (CMT). Scientists in…
The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…
Functional surgery can improve walking ability in people with Charcot-Marie-Tooth disease (CMT), and patients are generally satisfied with the outcomes,…
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
Using bioinformatics — computer-based analyses of biological data — scientists discovered 30 new genes that might be involved in…
This October, in observance of Charcot-Marie-Tooth disease (CMT) awareness month in Europe, the CMT&Me study is launching an…
CKD-504, a new compound that works to block the protein HDAC6, was found to restore myelination in cell and…
Mutations in the DST gene that affect the normal functioning of nerve fibers can cause Charcot-Marie-Tooth disease…